These trials, including STEP-1 through STEP-6, highlighted semaglutides superiority over placebo and other treatments, such as liraglutide, in promoting weight loss and enhancing cardiometabolic parameters, including blood pressure and lipid profiles [6][15]
Currently, no large-scale clinical trials have directly examined the relationship between GLP-1 agonists and acne, and these medications are not licensed for dermatological indications
What we do have is two strong signals pointing the other way
Patients who frame ongoing treatment as medical management of chronic disease report less stress and better adherence than those who see it as personal failure requiring pharmaceutical correction
These results highlight semaglutides early action on decreasing major cardiovascular events, with significant benefits already evident by the first 6 months, and for some, even earlier, even before any major weight loss and before most patients would have been titrated to their full target dose of 2.4 mg, said lead author Dr Jorge Plutzky, Director of Preventive Cardiology, Cardiovascular Medicine at Brigham and Womens Hospital, Boston, MA, USA and a member of SELECT Steering Committee
Using three-dimensional stereoscopic camera technology, I could quantify and localize specific fat compartments that seemed to change the most
)
